By Colin Kellaher
Insmed has won Food and Drug Administration priority review for its application seeking approval of its brensocatib drug candidate for patients with the chronic inflammatory condition non-cystic fibrosis bronchiectasis.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.
Insmed on Thursday said the FDA set a target action date of Aug. 12, adding that the agency hasn't indicated whether it will convene an advisory committee to discuss the application.
The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' airways to permanently widen and make the lungs more susceptible to infection.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 06, 2025 08:30 ET (13:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。